Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a chromium blend help menopausal women maintain muscle?

NCT ID NCT07402382

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether an amylopectin chromium blend can improve how the body uses protein and controls blood sugar in women going through or past menopause. Sixty women aged 40-65 will take the supplement or a placebo after a short exercise session. The goal is to see if this simple supplement can support muscle health and metabolic function during midlife.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
amylopectin-chromium blend (dietary supplement)
What this could lead to
If it works, this could point toward a nutritional strategy to support muscle maintenance and metabolic health in midlife women.
What could go wrong
This is a small, early-stage study (60 participants) testing an acute effect, not a long-term treatment. Results may not translate to real-world benefits or generalise beyond this group.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 70 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria:• Women aged 40-65 years who meet either of the following menstrual-history criteria: * ≥ 60 days but \< 12 months of amenorrhea (late perimenopause) * Women with ≥ 12 months of spontaneous amenorrhea (post-menopausal) * No more than 3 days per week of structured physical activity * Provide voluntary signed and dated informed consent. * Be in good health and able to participate in an exercise bout as determined by assessment, medical history, and routine blood chemistries. * Between the of 40 and 65 years of age (inclusive). * Body Mass Index of 18.5-34.9 (inclusive). * Body weight of at least 110 pounds. * Normotensive (seated, resting systolic blood pressure \<140 mm Hg and diastolic blood pressure \< 90 mm Hg. If the first measurement is slightly elevated above these limits, the subject will be given a brief (5-minute) rest period, and two more measurements will be taken. The average of all three measurements will be used to determine eligibility. * Normal supine, resting heart rate (\<90 per minute). * Subject agrees to follow standardized controlled diet for 3 days and maintain existing dietary patterns on other days throughout the study period. * Subject is willing and able to comply with the study protocol. * Able to provide an adequate blood draw. * If a dietary supplement was initiated within the past month, the participant is willing to discontinue supplement use followed by a 2-week washout prior to participation in the study. Note: A generic multivitamin is allowed. * Refrain from caffeine, exercise, and alcohol for 24 hours prior, and fast for 10 hours prior to each visit. Exclusion Criteria: * Current use of any dietary ingredient that impacts glucose control or insulin sensitivity. * Current vegans or vegetarians. * Intolerance to dairy foods/drinks. * Smokes more than 10 cigarettes per day or uses other nicotine products (i.e. vape, patch) that deliver a similar amount of nicotine. * History of malignancy in the previous 5 years except for non-melanoma skin cancer (basal cell cancer or squamous cell cancer of the skin). * Prior gastrointestinal bypass surgery (Lapband, etc.). * Individuals using any kind of GLP-1 medications. * Other known gastrointestinal or metabolic diseases that might impact nutrient absorption or metabolism, e.g. electrolyte abnormalities, diabetes, thyroid disease, adrenal disease, hypogonadism, short bowel syndrome, diarrheal illnesses, history of colon resection, gastric ulcer, reflux disease, gastroparesis, Inborn-Errors-of-Metabolism (such as PKU). * Individuals who have gained or lost more than 10 pounds within the last 30 days. * Individuals who are cognitively impaired and/or who are unable to give informed consent. * Chronic medically diagnosed inflammatory condition or disease (e.g. rheumatoid arthritis, Crohn's disease, ulcerative colitis, Lupus, HIV/AIDS, etc.). * Medical history of hepatorenal, musculoskeletal, autoimmune, or neurologic disease. * Known sensitivity to any ingredient in the test formulations as listed in the Certificates-of-Analysis. * Any other diseases or conditions that, in the opinion of the medical staff, could confound the primary endpoint or place the subject at increased risk of harm if they were to participate.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glucose monitoring, continuous are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The Center for Applied Health Sciences

    RECRUITING

    Canfield, Ohio, 44406, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.